CIK 0001582313
- Large accelerated filer
Xenon Pharmaceuticals Inc.
Sign in to watch- Ticker
- XENE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- Operating
- EIN
- 980661854
- Phone
- +1 604-484-3300
- Business address
- 200 - 3650 GILMORE WAY, BURNABY, British Columbia, Canada
- Open-market buys, last 90 days
- $1,681,140
- in 2 filings
- Open-market sales, last 90 days
- $425,829
- in 1 filing, $426K under 10b5-1 plans
Net +$1,255,311. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-10-28 | TARNOW MICHAEL M Director | Exercise or conversion | +5,144 | $3.76 | $19K | 80,001 |
| 2020-10-28 | TARNOW MICHAEL M Director | Gift | −10,288 | 69,713 | ||
| 2020-10-28 | TARNOW MICHAEL M Director | Exercise or conversion · Stock Option (Right to Buy) | −5,144 | 0 | ||
| 2020-10-28 | TARNOW MICHAEL M Director | Exercise or conversion · Stock Option (Right to Buy) | −5,144 | 0 | ||
| 2020-10-28 | PATOU GARY Director | Exercise or conversion | +2,057 | $3.76 | $8K | 23,573 |
| 2020-10-28 | PATOU GARY Director | Exercise or conversion · Stock Option (Right to Buy) | −2,057 | 0 | ||
| 2020-08-20 | PIMSTONE SIMON N. CEO | Other disposition | −45,000 | 210,186 | ||
| 2020-08-17 | Von Seggern Christopher Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2020-06-09 | TARNOW MICHAEL M Director | Exercise or conversion | +5,144 | $3.52 | $18K | 69,713 |
| 2020-06-09 | TARNOW MICHAEL M Director | Exercise or conversion · Stock Option (Right to Buy) | −5,144 | 0 | ||
| 2020-06-01 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Exercise or conversion | +8,230 | $3.56 | $29K | 18,426 |
| 2020-06-01 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Shares withheld for taxes | −1,630 | $13.70 | $22K | 16,796 |
| 2020-06-01 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Exercise or conversion · Stock Option (Right to Buy) | −8,230 | 0 | ||
| 2020-06-01 | PATOU GARY Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2020-06-01 | TARNOW MICHAEL M Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2020-06-01 | Svoronos Dawn Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2020-06-01 | Hayden Michael R Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2020-06-01 | GANNON STEVEN Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2020-06-01 | Desjardins Clarissa Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2020-06-01 | AZAB MOHAMMAD Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 |
Page 22 of 27 · 536 trades